EcoDrugPlus

Phospholipase A2 Group V

Ensembl ID : ENSMMNG00015007766
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSMMNG00015017360
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSMMNG00015006694
Gene Symbol: PLA2G10
3 Cross references
249 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSMMNG00015001134
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSMMNG00015011493
Gene Symbol: PLG
2 Cross references
240 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSMMNG00015002398
Gene Symbol: PLAT
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSMMNG00015013167
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSMMNG00015002105
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSMMNG00015020223
Gene Symbol: PDGFB
3 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSMMNG00015010378
Gene Symbol: PLK1
3 Cross references
183 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSMMNG00015013092
Gene Symbol: PLK4
3 Cross references
208 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSMMNG00015008660
Gene Symbol: PARP1
3 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).